HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

S K Libutti Selected Research

Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)

1/2013Blockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activity.
12/2002Noninvasive fluorescent imaging reliably estimates biomass in vivo.
10/2002Improved antitumor response to isolated limb perfusion with tumor necrosis factor after upregulation of endothelial monocyte-activating polypeptide II in soft tissue sarcoma.
12/2001Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
4/2001Role of tumor necrosis factor on toxicity and cytokine production after isolated hepatic perfusion.
2/2001Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer.
1/2001Endothelial monocyte activating polypeptide II (EMAP II) enhances the effect of TNF on tumor-associated vasculature.
11/2000Technique and results of hyperthermic isolated hepatic perfusion with tumor necrosis factor and melphalan for the treatment of unresectable hepatic malignancies.
8/2000A phase I-II study of isolated hepatic perfusion using melphalan with or without tumor necrosis factor for patients with ocular melanoma metastatic to liver.
1/2000Current status of isolated hepatic perfusion with or without tumor necrosis factor for the treatment of unresectable cancers confined to liver.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


S K Libutti Research Topics

Disease

29Neoplasms (Cancer)
08/2015 - 01/2000
6Melanoma (Melanoma, Malignant)
01/2013 - 01/2000
4Necrosis
06/2013 - 07/2000
3Sarcoma (Soft Tissue Sarcoma)
10/2002 - 01/2000
3Colorectal Neoplasms (Colorectal Cancer)
12/2001 - 04/2001
3Neoplasm Metastasis (Metastasis)
10/2001 - 02/2001
2Colonic Neoplasms (Colon Cancer)
12/2001 - 12/2001
2Multiple Endocrine Neoplasia Type 1
12/2001 - 09/2000
2Hyperthermia
02/2001 - 11/2000
2Inflammation (Inflammations)
01/2001 - 09/2000
2Vaccinia
07/2000 - 01/2000
1Adenocarcinoma
08/2015
1Neuroendocrine Tumors (Neuroendocrine Tumor)
08/2015
1Pancreatic Neoplasms (Pancreatic Cancer)
08/2015
1Hepatocellular Carcinoma (Hepatoma)
06/2013
1Carcinoma (Carcinomatosis)
03/2007
1Hyperparathyroidism
12/2001
1Disease Progression
10/2001
1Zollinger-Ellison Syndrome (Syndrome, Zollinger-Ellison)
06/2001
1Hyperplasia
01/2001
1Islet Cell Adenoma (Islet Cell Tumors)
01/2001
1Parathyroid Neoplasms (Parathyroid Neoplasm)
01/2001
1Vascular Remodeling
01/2001
1Fibrosarcoma
01/2001
1Kidney Neoplasms (Kidney Cancer)
12/2000
1Adenoma (Adenomas)
12/2000
1Renal Cell Carcinoma (Grawitz Tumor)
12/2000
1Insulinoma
09/2000
1Hypoglycemia (Reactive Hypoglycemia)
09/2000
1Wounds and Injuries (Trauma)
06/2000
1Breast Neoplasms (Breast Cancer)
03/2000

Drug/Important Bio-Agent (IBA)

10Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
01/2013 - 01/2000
7EndostatinsIBA
10/2001 - 03/2000
6Proteins (Proteins, Gene)FDA Link
01/2013 - 03/2000
6Melphalan (Alkeran)FDA LinkGeneric
12/2001 - 01/2000
5CytokinesIBA
10/2002 - 07/2000
5member 1 small inducible cytokine subfamily EIBA
10/2002 - 07/2000
3Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
10/2001 - 12/2000
2Thromboplastin (Tissue Factor)IBA
10/2002 - 07/2000
2Thymidine KinaseIBA
12/2001 - 01/2000
2EnzymesIBA
10/2001 - 07/2000
2Insulin (Novolin)FDA Link
01/2001 - 09/2000
1Peptides (Polypeptides)IBA
08/2015
1AntibodiesIBA
08/2015
1AntigensIBA
08/2015
1Bispecific AntibodiesIBA
08/2015
1Somatostatin (Somatotropin Release-Inhibiting Factor)IBA
08/2015
1Radioisotopes (Radionuclides)IBA
08/2015
1liposomal doxorubicin (Doxil)FDA Link
06/2013
1LCL161IBA
01/2013
11-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine- vasopressin (AAVP)IBA
01/2013
1Glutathione Transferase (Glutathione S-Transferase)IBA
03/2007
1ParaffinIBA
10/2002
1vaccinia growth factorIBA
12/2001
1technetium Tc-99m arcitumomabFDA Link
12/2001
1Carcinoembryonic AntigenIBA
12/2001
1InterferonsIBA
12/2001
1Deoxyglucose (2 Deoxy D glucose)IBA
12/2001
1arcitumomabFDA Link
12/2001
1N 30IBA
12/2001
1Angiogenesis InhibitorsIBA
07/2001
1GastrinsIBA
06/2001
1P-30 composite resin (P 30)IBA
06/2001
1Peptide Hydrolases (Proteases)FDA Link
04/2001
1Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)IBA
04/2001
1Collagen Type XVIII (Type XVIII Collagen)IBA
04/2001
1Floxuridine (FUdR)FDA LinkGeneric
02/2001
1Biological ProductsIBA
02/2001
1Leucovorin (Folinic Acid)FDA Link
02/2001
1Recombinant ProteinsIBA
01/2001
1A-factor (Streptomyces)IBA
01/2001
1Phosphotransferases (Kinase)IBA
12/2000
1Interleukin-8 (Interleukin 8)IBA
12/2000
1ChemokinesIBA
12/2000
1E-SelectinIBA
12/2000
1Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
12/2000
1Pharmaceutical PreparationsIBA
10/2000
1Glucose (Dextrose)FDA LinkGeneric
09/2000
1ProinsulinIBA
09/2000
1H 85IBA
09/2000
1ProdrugsIBA
07/2000
1Type II Tumor Necrosis Factor ReceptorsIBA
07/2000
1AngiostatinsIBA
03/2000
1Liposomes (Liposome)IBA
03/2000
1LuciferasesIBA
01/2000
1Ficusin (Psoralen)IBA
01/2000

Therapy/Procedure

11Therapeutics
08/2015 - 06/2000
2Drug Therapy (Chemotherapy)
08/2015 - 02/2001
2Aftercare (After-Treatment)
12/2001 - 05/2000
2Laparotomy
12/2001 - 11/2000
1Biological Therapy
08/2015
1Cell- and Tissue-Based Therapy (Cell Therapy)
03/2015
1Immunotherapy
03/2015
1Radiofrequency Ablation
06/2013
1Parathyroidectomy
12/2001
1Subcutaneous Injections
07/2001
1Intraperitoneal Injections
07/2001
1Thymectomy
12/2000
1Sternotomy
12/2000
1Intravenous Injections
01/2000